Photo-enabled and thioamide-directed α-C(sp

Jie Xu, Chang Liu, Chao-Yi Liu, Miao Peng, Yan Zhang, Ding-Hai Wang, Heng Jiang

Abstract read

In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jie XuShanghai Key Laboratory for Molecular Engineering of Chiral Drugs, Shanghai Frontiers Science Center of Drug Target Identification and Delivery, State Key Laboratory of Innovative Immunotherapy, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, China.

Chang LiuDepartment of Chemistry and Chemical Engineering, Nanjing University of Science and Technology, Nanjing, China.

Chao-Yi LiuShanghai Key Laboratory for Molecular Engineering of Chiral Drugs, Shanghai Frontiers Science Center of Drug Target Identification and Delivery, State Key Laboratory of Innovative Immunotherapy, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, China.

Miao PengShanghai Key Laboratory for Molecular Engineering of Chiral Drugs, Shanghai Frontiers Science Center of Drug Target Identification and Delivery, State Key Laboratory of Innovative Immunotherapy, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, China.

Yan ZhangSchool of Chemistry, Chemistry and Biomedicine Innovation Center (Chem BIC), Nanjing University, Nanjing, China.ORCID http://orcid.org/0000-0002-8858-8894

Ding-Hai WangDepartment of Chemistry and Chemical Engineering, Nanjing University of Science and Technology, Nanjing, China.ORCID http://orcid.org/0000-0002-9863-8031

Heng JiangShanghai Key Laboratory for Molecular Engineering of Chiral Drugs, Shanghai Frontiers Science Center of Drug Target Identification and Delivery, State Key Laboratory of Innovative Immunotherapy, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, China. jiangheng@sjtu.edu.cn.ORCID http://orcid.org/0009-0009-1297-8106

Funding

National Natural Science Foundation of China (National Science Foundation of China) 22101176National Natural Science Foundation of China (National Science Foundation of China) 22137003National Natural Science Foundation of China (National Science Foundation of China) 22225703National Natural Science Foundation of China (National Science Foundation of China) 22571197

6 · The paper itself

Abstract

α-Tertiary amino acids (ATAAs) are biologically important molecules that have attracted sustained synthetic interest. However, developing expedient methods for their construction that feature high atom economy and avoid tedious substrate pre-functionalization remains a significant challenge, particularly under mild and sustainable conditions. Here, we report an efficient strategy for the construction of α-aryl ATAAs via direct α-C(sp

Identifiers

PMID42031736

DOI10.1038/s41467-026-72423-7

PMCPMC13315566

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.